Literature DB >> 24399715

Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082.

Jolanta Konieczny1, Tomasz Lenda.   

Abstract

BACKGROUND: Metabotropic glutamate receptors (mGluRs) have been shown to be potential targets for numerous neurological diseases, including Parkinson's disease (PD). We previously reported that ACPT-1, a non-selective group III mGluRs agonist, injected locally into the globus pallidus, striatum or substantia nigra pars reticulata (SNr), significantly attenuated the haloperidol-induced catalepsy in rats. N,N'-dibenzhydryl-ethane-1,2-diamine dihydrochloride (AMN082) is a potent, brain penetrating mGluR7 agonist, selective over other mGluRs.
METHODS: The aim of the present study was to determine whether (1) activation of mGluR7 by systemic administration of AMN082 may produce antiparkinsonian-like effects in the haloperidol-induced catalepsy and reserpine-induced akinesia models in rats; (2) striatal and nigral mGluR7 is likely to contribute to such an effect.
RESULTS: We found that AMN082 (1 and 3 mg/kg) decreased the haloperidol (0.25 mg/kg)-induced catalepsy, but was not efficient in attenuating the reserpine (2.5 mg/kg)-induced akinesia. When given locally, AMN082 also significantly diminished catalepsy in rats; however, its effective striatal doses were 10-fold lower than those used in the SNr (2.5 and 7.5 pmol/0.5 μl/ side vs. 25 and 75 pmol/0.5 μl/side, respectively).
CONCLUSION: The above findings support the idea that the activation of mGluR7 can produce antiparkinsonian-like effects in rats. Furthermore, our results indicate contribution of both striatal and nigral mGluR7 to the anticataleptic effects of AMN082.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24399715     DOI: 10.1016/s1734-1140(13)71477-4

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  5 in total

Review 1.  The Modulation of Pain by Metabotropic Glutamate Receptors 7 and 8 in the Dorsal Striatum.

Authors:  Serena Boccella; Ida Marabese; Francesca Guida; Livio Luongo; Sabatino Maione; Enza Palazzo
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

Review 2.  Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.

Authors:  Fabio Del Bello; Mario Giannella; Gianfabio Giorgioni; Alessandro Piergentili; Wilma Quaglia
Journal:  Biomolecules       Date:  2019-04-09

Review 3.  Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia.

Authors:  Andrea Fabbrini; Andrea Guerra
Journal:  J Exp Pharmacol       Date:  2021-04-29

4.  Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7.

Authors:  Nidhi Jalan-Sakrikar; Julie R Field; Rebecca Klar; Margrith E Mattmann; Karen J Gregory; Rocio Zamorano; Darren W Engers; Sean R Bollinger; C David Weaver; Emily L Days; L Michelle Lewis; Thomas J Utley; Miguel Hurtado; Delphine Rigault; Francine Acher; Adam G Walker; Bruce J Melancon; Michael R Wood; Craig W Lindsley; P Jeffrey Conn; Zixiu Xiang; Corey R Hopkins; Colleen M Niswender
Journal:  ACS Chem Neurosci       Date:  2014-10-09       Impact factor: 4.418

5.  The neuroprotective effects of AMN082 on neuronal apoptosis in rats after traumatic brain injury.

Authors:  Chung-Che Lu; Tee-Tau Eric Nyam; Jinn-Rung Kuo; Yao-Lin Lee; Chung-Ching Chio; Che-Chuan Wang
Journal:  BMC Neurosci       Date:  2021-06-25       Impact factor: 3.288

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.